A real-world study of immune thrombocytopenia management during the COVID-19 pandemic in the UK.
Br J Haematol
; 196(2): 351-355, 2022 01.
Article
in English
| MEDLINE | ID: covidwho-1373796
ABSTRACT
The COVID-19 pandemic has created many challenges in the management of immune thrombocytopenic purpura (ITP). The recommendation for avoidance of steroids by WHO led to the off-licence use, supported by NHS England, of thrombopoietin mimetics (TPO-RA) for newly diagnosed or relapsed ITP. This is a real-world prospective study which investigated the treatment patterns and outcomes in this setting. Twenty-four hospitals across the UK submitted 343 cases. Corticosteroids remain the mainstay of ITP treatment, but TPO-RAs were more effective. Incidental COVID-19 infection was identified in a significant number of patients (9·5%), while 14 cases were thought to be secondary to COVID-19 vaccination.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Purpura, Thrombocytopenic, Idiopathic
/
Pandemics
/
COVID-19
Type of study:
Cohort study
/
Observational study
/
Prognostic study
Topics:
Long Covid
/
Vaccines
Country/Region as subject:
Europa
Language:
English
Journal:
Br J Haematol
Year:
2022
Document Type:
Article
Affiliation country:
Bjh.17804
Similar
MEDLINE
...
LILACS
LIS